In the near term we expect to secure a number of new third party billing agreements with large and well recognised Chinese private and government companies. The benefits of subscription billing continues to be apparent in the second half with continuing subscription-based revenue generated in January confirming the success of the company’s business model.
- Forums
- ASX - By Stock
- ODA
- Ann: Half Year Accounts
Ann: Half Year Accounts, page-2
Featured News
Add ODA (ASX) to my watchlist
(20min delay)
|
|||||
Last
13.5¢ |
Change
0.005(3.85%) |
Mkt cap ! $22.83M |
Open | High | Low | Value | Volume |
13.5¢ | 13.5¢ | 13.5¢ | $807 | 5.981K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3740 | 13.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
15.5¢ | 10131 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3740 | 0.135 |
1 | 54367 | 0.130 |
2 | 32000 | 0.125 |
3 | 93000 | 0.120 |
1 | 100000 | 0.086 |
Price($) | Vol. | No. |
---|---|---|
0.155 | 10131 | 1 |
0.160 | 61533 | 2 |
0.165 | 5807 | 1 |
0.180 | 26234 | 1 |
0.220 | 16153 | 1 |
Last trade - 12.55pm 15/11/2024 (20 minute delay) ? |
Featured News
ODA (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online